NASDAQ
01.04.25
20:42 Uhr
1,290 US-Dollar
+0,070
+5,74 %
+5,74 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| Mo | TELA Bio introduces larger sizes for soft tissue reconstruction | 1 | Investing.com | ||
| Mo | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mo | TELA Bio, Inc.: TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex PRS for Plastic and Reconstructive Surgery | 1 | GlobeNewswire (USA) | ||
| 22.03. | TELA Bio, Inc. (NASDAQ:TELA) Q4 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
| 21.03. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21.03. | TELA Bio, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 21.03. | Tela Bio slumps after Q4 miss as Piper Sandler downgrades | 2 | Seeking Alpha | ||
| 21.03. | Canaccord cuts TELA Bio stock target to $7, maintains Buy | 3 | Investing.com | ||
| 21.03. | TELA Bio stock price target cut to $7 by Citizens JMP | 2 | Investing.com | ||
| 21.03. | Piper Sandler cuts TELA Bio stock rating, slashes price target | 1 | Investing.com | ||
| 21.03. | TELA Bio sees 23-27% revenue growth for 2025 with expanded sales strategy | 2 | Seeking Alpha | ||
| 20.03. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.03. | TELA Bio, Inc.: TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results | 159 | GlobeNewswire (Europe) | MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 27.02. | TELA Bio, Inc.: TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results | 1 | GlobeNewswire (USA) | ||
| 21.02. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 143 | GlobeNewswire (Europe) | MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 24.01. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 161 | GlobeNewswire (Europe) | MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 13.12.24 | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 188 | GlobeNewswire (Europe) | MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 08.11.24 | TELA Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.24 | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.11.24 | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 195 | GlobeNewswire (Europe) | MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 25,355 | -3,26 % | Moderna-Aktie leicht im Minus (29,9070 €) | Der Anteilsschein von Moderna notiert heute ein wenig leichter. Der jüngste Kurs betrug 32,24 US-Dollar. Für der Anteilsschein von Moderna steht gegenwärtig ein Abschlag von 4,13 Prozent zu Buche. Die... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,066 | -1,90 % | PacBio Appoints Jim Gibson As New CFO | WASHINGTON (dpa-AFX) - Life science technology company PacBio, Inc. (PACB) announced Thursday the appointment of Jim Gibson as the company's new Chief Financial Officer, effective as of his... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,270 | -3,79 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update | Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - March 31, 2025)... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 0,560 | -6,28 % | CytomX Therapeutics Aktie: Schwieriger als gedacht! | Biotechnologieunternehmen strafft Organisation um 40 Prozent, priorisiert Krebswirkstoff-Konjugat und verlängert Finanzierungshorizont bis ins zweite Quartal 2026 CytomX Therapeutics befindet sich in... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,220 | -4,01 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| RAPT THERAPEUTICS | 1,140 | +4,59 % | RAPT Therapeutics, Inc. - 8-K, Current Report | ||
| TC BIOPHARM | 0,825 | 0,00 % | TC BioPharm: TCBP Announces Transition from Nasdaq to OTC Markets | EDINBURGH, Scotland, March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology... ► Artikel lesen | |
| QIAGEN | 37,135 | +1,25 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
| TEMPUS AI | 46,695 | -3,20 % | Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? | ||
| BIOAFFINITY TECHNOLOGIES | 1,050 | +281,82 % | RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 13,940 | -12,38 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 6,125 | +1,07 % | Evotec, NetraMark, Novo Nordisk - vom Labor zur goldenen digitalen Zukunft mit Künstlicher Intelligenz | Die Pharmabranche erlebt eine Revolution, die alles verändert! Künstliche Intelligenz jagt durch die Labore und schneidet alte Zöpfe ab. Algorithmen durchforsten Milliarden chemischer Strukturen in... ► Artikel lesen | |
| BIONTECH | 84,90 | +2,97 % | DEUTSCHE BANK RESEARCH stuft Biontech auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Biontech auf "Buy" mit einem Kursziel von 140 US-Dollar belassen. Analyst Emmanuel Papadakis befasste sich in einer am Mittwoch... ► Artikel lesen | |
| BEAM THERAPEUTICS | 17,610 | -9,90 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| BB BIOTECH | 31,900 | +0,31 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen |
Das Unternehmen TELA BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,290 Euro und damit +5,74 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.
